3.44 USD
↗ 0.03 (0.88%)AT CLOSE (11:59 AM EDT)
Rocket Pharmaceuticals, Inc. Common Stock
RCKTNASDAQ • USD
3.41
↘ 0.03 (0.84%)
POST MARKET (AS OF 07:05 PM EDT)
Post Market
AS OF 07:05 PM EDT
3.41
↘ 0.03 (0.84%)
Market: CLOSED
Rocket Pharmaceuticals, Inc. Common Stock (RCKT) trades at $3.43 per share. Both sides of the analysis point lower: technicals flash "Strong Sell" and fundamentals confirm with a "Sell" reading. Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. The stock looks compelling on valuation, with multiples below sector averages across P/E, P/B, and EV/EBITDA.
Technical & fundamental data as of Jul 17, 2026.
Open?$3.34
High?$3.45
Low?$3.26
Prev. Close?$3.41
Volume?1.5M
Avg. Volume?2.9M
VWAP?$3.38
Rel. Volume?0.52x
Bid / Ask
Bid?$2.89 × 100
Ask?$3.90 × 100
Spread?$1.01
Midpoint?$3.40
Valuation & Ratios
Market Cap?372.4M
Shares Out?109.2M
Float?84.0M
Float %?77.0%
P/E Ratio?N/A
P/B Ratio?1.56
EPS?-$1.92
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
Themes
Employees
202
Market Cap
372.4M
Industry
PHARMACEUTICAL PREPARATIONS
Website
Listed
2015-02-18
Address
350 FIFTH AVENUE
NEW YORK, NY 10118
Phone: 646-440-9100
NEW YORK, NY 10118
Phone: 646-440-9100
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?0
Momentum?50
Short Sent.?41
Piotroski F-Score?0/9Weak
Altman Z-Score?-4.56Distress
Confidence?56%Low
Short InterestSqueeze Risk
Short % of Float?21.61%Squeeze Risk
Short Interest?18.2M
Days to Cover?5.0
Free Float84.0M
Avg Daily Volume3.6M
Settlement Date2026-06-30
Financial Health
Current Ratio?6.12Strong
Quick Ratio?6.12Strong
Cash Ratio?2.03Strong
Debt/Equity?0.09Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score100/100
P/E?N/A▾
P/B?1.56CHEAP▾
Peers100
S&P86
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-1.7CHEAP▾
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?-88.0%WEAK▾
S&P3
ROA?-73.4%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-179787000
Enterprise Value?$344.0M
Fundamentals ratios updated end of day